Resources
11 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 7/28/2023 (updated 3/26/2024)
Researchers interviewed 20 individuals – clinicians, peer support specialists, cultural practitioners, and others familiar with OUD treatment – in a Minnesota tribal community. The Cascade of Care model measures the quality of outcomes at each stage of treatment, from diagnosis to long-term maintenance, and was first proposed in 1998 as an approach to care for HIV/AIDS.
Posted 7/25/2022 (updated 3/27/2024)
Researchers used claims and enrollment data from Tennessee’s Medicaid program to develop an algorithm measuring five types of ACEs: maltreatment and peer violence, foster care and family disruption, maternal mental illness, maternal substance use disorder, and abuse of the mother. Recent recommendations from the National Advisory Committee on Rural Health & Human Services included stronger data collection that analyzes rural-urban differences.
Posted 3/16/2022 (updated 3/27/2024)
Background: Sharp exacerbations of the US overdose crisis are linked to polysubstance use of synthetic compounds. Xylazine is a veterinary tranquilizer, long noted in the street opioid supply of Puerto Rico, and more recently Philadelphia. Yet its national trends, geographic distribution, and health risks are poorly characterized. Methods: In this sequential mixed-methods study, xylazine was increasingly observed by ethnographers in Philadelphia among drug-sellers and people who inject drugs (PWID). Subsequently, we systematically searched for records describing xylazine-present overdose mortality across the US and assessed time trends and overlap with other drugs
Posted 1/26/2022 (updated 3/26/2024)
The Centers for Disease Control and Prevention (CDC) looked at data from six states mandated to report on neonatal abstinence syndrome (NAS), a condition that occurs when newborn babies experience withdrawal from drugs. A previous study of these states – Arizona, Florida, Georgia, Kentucky, Tennessee, and Virginia – indicated that the reporting helped determine the prevalence of NAS and identify communities more severely affected. The current report is based on answers to a follow-up questionnaire given to epidemiologists and birth defects program managers from the same six states.
Posted 5/26/2021 (updated 4/10/2024)
Opioid dependence is a chronic relapsing disorder with considerable individual and global public health burden. The current standard of care for opioid dependence includes treatment with methadone or sublingual (SL) buprenorphine or buprenorphine-naloxone (hereafter, buprenorphine), combined with psychosocial and behavioral support. Both medications are associated with reductions in mortality, illicit opioid use, bloodborne viral infections, and criminal behavior as well as better cost-effectiveness than no treatment or psychosocial treatment alone. Buprenorphine is a partial μ-opioid receptor agonist, enabling office-based treatment for nonsupervised or take-home use of the medication. However, SL formulations of buprenorphine are prone to nonmedical use (eg, injecting, diversion), prompting models of care, particularly in the early phases of treatment, requiring regular attendance at clinics or pharmacies for administration of doses.
Posted 3/2/2021 (updated 4/4/2024)
In light of the accelerating and rapidly evolving overdose crisis in the United States (US), new strategies are needed to address the epidemic and to efficiently engage and retain individuals in care for opioid use disorder (OUD). Moreover, there is an increasing need for novel approaches to using health data to identify gaps in the cascade of care for persons with OUD.
Posted 3/1/2021 (updated 4/4/2024)
o CAST (calculating for an adequate system tool) produces community-specific assessments of the capacity of the components of a community substance abuse care system. CAST generates recommendations by the application of social and community determinants of health as risk coefficients to each estimate of component need. CAST can assist public health practitioners in evaluation and improvement of the capacity of community-based, substance abuse care systems.
Posted 10/12/2020 (updated 3/29/2024)
The present two-fold study “Speed Limits – Harm reduction for people who use stimulants” significantly contributes to closing the gap of knowledge about which existing harm reduction interventions are effective for people who use stimulant drugs.
Posted 8/11/2020 (updated 3/28/2024)
Corporation for Supportive Housing (CSH) developed a Racial Disparities and Disproportionality Index that looks at 16 unique systems and measures whether a racial and/or ethnic group’s representation in a particular public system is proportionate to, over or below their representation in the overall population and also allows for the examination of systematic differences between groups and geographies .
Posted 5/19/2020 (updated 3/28/2024)
In 2016, the United States Congress authorized and appropriated funding to fight the opioid epidemic through the Department of Health and Human Services . Among other initiatives, the Comprehensive Addiction and Recovery Act (CARA) gave the Substance Abuse and Mental Health Services Administration authority and support to implement new grant programs focused on preventing overdose and treating individuals with OUD.